Mylan and Pfizer are still struggling with manufacturing issues for the EpiPen anti-allergy injector as the critical back-to-school season gets underway and a rival generic product hits the market. EpiPens, which can help stop a severe or life-threatening allergic reaction, have been hard to get since at least May 2018, when the U.S.